American Society of Hirudotherapy

Leech Extract Anti-Atherosclerotic Pharmacology

Leech-extract anti-atherosclerotic pharmacology (composite topic entry; no single primary publication attributed).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Expert consensus
Drug vs leech
Leech-derived crude extract
Safety domains
Bleeding

Clinical translation limit

Review evidence does NOT establish clinical efficacy for atherosclerosis prevention or treatment. Atherosclerosis is not an FDA-cleared K040187 indication.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
Hirudo medicinalis (composite)

Biological Targets

  • → platelet aggregation; endothelial inflammation; fibrinogen; serum lipids

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.